Epcoritamab Shows Promise in High-risk Burkitt Lymphoma with DA-EPOCH-R in Phase II Trial
The phase II BEDROCK study is evaluating the efficacy of epcoritamab combined with DA-EPOCH-R in high-risk Burkitt lymphoma patients.
Indication
Clinical and regulatory intelligence for Burkitt Lymphoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.